| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0006-8993(01)02484-2 |
| P698 | PubMed publication ID | 11423097 |
| P2093 | author name string | Walker DG | |
| Fisher A | |||
| Beach TG | |||
| Potter PE | |||
| Sue LI | |||
| P2860 | cites work | Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors | Q24294213 |
| Cellular mechanisms of beta-amyloid production and secretion | Q33740154 | ||
| Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. | Q34148264 | ||
| Modulation of amyloid precursor protein processing by compounds with various mechanisms of action: detection by liquid phase electrochemiluminescent system | Q36897963 | ||
| Increased beta-amyloid precursor protein mRNA in the rat cerebral cortex and hippocampus after chronic systemic atropine treatment | Q38357595 | ||
| Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells | Q41361359 | ||
| Cholinesterase inhibitors increase secretion of APPs in rat brain cortex | Q42276951 | ||
| Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. | Q48499472 | ||
| Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions | Q48696243 | ||
| Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 | ||
| Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. | Q51990804 | ||
| Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. | Q52171785 | ||
| Regulated secretion of beta-amyloid precursor protein in rat brain | Q71511604 | ||
| Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain | Q73274148 | ||
| Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion | Q77499756 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| P304 | page(s) | 220-223 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists | |
| P478 | volume | 905 |
| Q40650293 | 6beta-acetoxy nortropane regulated processing of amyloid precursor protein in CHOm1 cells and rat brain |
| Q42184020 | A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha |
| Q34147757 | AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease |
| Q34551487 | APP as a Protective Factor in Acute Neuronal Insults |
| Q48226341 | Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study. |
| Q26829267 | Alzheimer's therapeutics: translation of preclinical science to clinical drug development |
| Q38788038 | Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease |
| Q37961834 | Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease |
| Q28287090 | Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease |
| Q33830572 | Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease |
| Q36891064 | Curcumin: a natural substance with potential efficacy in Alzheimer's disease |
| Q33793579 | Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo |
| Q42810444 | Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. |
| Q35031640 | Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease |
| Q35103820 | In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors |
| Q48250501 | L-Satropane Prevents Retinal Neuron Damage by Attenuating Cell Apoptosis and Aβ Production via Activation of M1 Muscarinic Acetylcholine Receptor. |
| Q42131298 | Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline |
| Q35538840 | M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy |
| Q40146616 | M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity. |
| Q38192962 | M1 muscarinic acetylcholine receptor in Alzheimer's disease |
| Q40390510 | Noradrenergic sympathetic sprouting and cholinergic reinnervation maintains non-amyloidogenic processing of AβPP. |
| Q37446075 | Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults |
| Q35995627 | Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease |
| Q43720996 | Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. |
| Q55080849 | The Neurotoxic Role of Extracellular Tau Protein. |
| Q44108034 | The effect of scopolamine in older rabbits tested in the 750 ms delay eyeblink classical conditioning procedure |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q37980501 | Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression |
| Q38060562 | Wnt signaling: role in Alzheimer disease and schizophrenia |
| Q39774300 | [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors |
Search more.